Related Experiment Video
Updated: Apr 8, 2026

Optogenetic Phase Transition of TDP-43 in Spinal Motor Neurons of Zebrafish Larvae
Published on: February 25, 2022
PABPN1 suppresses TDP-43 toxicity in ALS disease models
Ching-Chieh Chou1, Olga M Alexeeva2, Shizuka Yamada3
1Department of Cell Biology, Center for Neurodegenerative Disease, Emory University School of Medicine, Atlanta, GA 30322, USA.
Abstract:
TAR DNA-binding protein 43 (TDP-43) is a major disease protein in amyotrophic lateral sclerosis (ALS) and related neurodegenerative diseases. Both the cytoplasmic accumulation of toxic ubiquitinated and hyperphosphorylated TDP-43 fragments and the loss of normal TDP-43 from the nucleus may contribute to the disease progression by impairing normal RNA and protein homeostasis. Therefore, both the removal of pathological protein and the rescue of TDP-43 mislocalization may be critical for halting or reversing TDP-43 proteinopathies. Here, we report poly(A)-binding protein nuclear 1 (PABPN1) as a novel TDP-43 interaction partner that acts as a potent suppressor of TDP-43 toxicity. Overexpression of full-length PABPN1 but not a truncated version lacking the nuclear localization signal protects from pathogenic TDP-43-mediated toxicity, promotes the degradation of pathological TDP-43 and restores normal solubility and nuclear localization of endogenous TDP-43. Reduced levels of PABPN1 enhances the phenotypes in several cell culture and Drosophila models of ALS and results in the cytoplasmic mislocalization of TDP-43. Moreover, PABPN1 rescues the dysregulated stress granule (SG) dynamics and facilitates the removal of persistent SGs in TDP-43-mediated disease conditions. These findings demonstrate a role for PABPN1 in rescuing several cytopathological features of TDP-43 proteinopathy by increasing the turnover of pathologic proteins.
Insights
Poly(A)-binding protein nuclear 1 (PABPN1) suppresses toxic TDP-43 proteinopathy in neurodegenerative diseases like ALS. Overexpressing PABPN1 clears pathological TDP-43 and restores normal protein function, offering a potential therapeutic strategy.
Area of Science:
- Neurobiology
- Molecular Biology
- Genetics
Background:
- TAR DNA-binding protein 43 (TDP-43) accumulation and mislocalization are key features of neurodegenerative diseases, including amyotrophic lateral sclerosis (ALS).
- Impaired RNA and protein homeostasis due to TDP-43 dysfunction contribute to disease progression.
- Targeting TDP-43 pathology is crucial for halting or reversing neurodegenerative conditions.
Purpose of the Study:
- To identify novel TDP-43 interaction partners that can suppress TDP-43 toxicity.
- To investigate the role of poly(A)-binding protein nuclear 1 (PABPN1) in mitigating TDP-43 proteinopathies.
Main Methods:
- Investigated PABPN1 as a TDP-43 interaction partner.
- Utilized cell culture and Drosophila models of ALS.
- Assessed the effects of PABPN1 overexpression on TDP-43 toxicity, localization, degradation, and stress granule dynamics.
Main Results:
- PABPN1 acts as a potent suppressor of TDP-43 toxicity.
- Overexpression of full-length PABPN1, but not a truncated mutant, protects against TDP-43-mediated toxicity.
- PABPN1 promotes the degradation of pathological TDP-43, restores its normal nuclear localization, and rescues dysregulated stress granule dynamics.
Conclusions:
- PABPN1 is a novel therapeutic target for TDP-43 proteinopathies.
- PABPN1 enhances the turnover of pathological proteins, offering a strategy to reverse cytopathological features in ALS and related diseases.

